Lack of association between the GRP78 polymorphisms in the promoter and 3' UTR and susceptibility to chronic HBV infection in a Chinese Han population

Xiao Zhu*†1, Dong-Pei Li†2, Wen-Guo Fan2, Marie CM Lin3,5, Jin-Long Wang†, Sheng-Qu Lin1, Jian-Qing Huang1 and Hsiang-Fu Kung4

Abstract

Background: Hepatitis B virus (HBV) infection causes large amount of unfolding or false-folding protein accumulation in the endoplasmic reticulum (ER), which in turn induces the expression of glucose-regulated protein 78 (GRP78). The aim in the present study was to analyse the potential association between GRP78 single-nucleotide polymorphisms (SNPs) and the risk of HBV infection.

Methods: The associations between seven common GRP78 polymorphisms in the promoter (rs391957, rs17840762, rs17840761, rs11355458) and in the 3' untranslated region (UTR) (rs16927997, rs1140763, rs12009) and possible risk of chronic HBV infection were assessed in a case-control study. 496 cases and 539 individually matched healthy controls were genotyped.

Results: Overall, no associations were observed in genotypic analyses. In addition, haplotypes and diplotypes combining those SNPs in the promoter or in the 3' UTR in high linkage disequilibrium (LD) were also not associated with HBV risk.

Conclusion: These observations do not support a role for GRP78 polymorphisms in HBV infection in a predominantly Chinese Han population.

Background

Hepatitis B virus (HBV) infection is one of the major infectious diseases that may lead to chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC) [1]. Approximately 30% of the world’s population has been infected with HBV and approximately 350 million are persistent carriers. The mechanisms underlying resolution of acute HBV infection or its progression to chronicity remain undetermined [2]. Approximately 90% of infants infected from HBV e antigen (HBeAg) positive mothers will fail to achieve clearance and develop persistent HBV infection. Whereas, for adults, the majority of HBV-infected individuals achieve clearance with just less than 10% becoming persistent carriers[3].

Glucose-regulated protein 78 (GRP78), also recognized as immunoglobulin heavy-chain binding protein (BiP) as it was found bound to immunoglobulin heavy chains in pre-B cells, is known to be induced in the endoplasmic reticulum (ER) compartment by a variety of stresses [4]. These stress signals include glucose starvation, ER Ca²⁺ depletion, virus infection or cancer progress which leads to accumulation of misfolded proteins in the ER. It has been shown that GRP78 functions as an antiapoptotic chaperone playing a key role in maintaining the proper functions of proteins and organelles [5].

Recent studies have emphasized that GRP78 play important roles in the progression inhibition of chronic HBV infection and HCC progression [6,7]. Overexpression of the large superficial protein of HBV which trans-
lateral from transcripts specified by a preS1 promoter in Huh7 cells results in a blockage of secretion of hepatitis B surface antigen (HBsAg), which leads to an accumulation of HBsAg in the ER lumen and in turn induces expression of GRP78 [8]. The presence of pre-S mutants of HBV in sera and tissues was related to a high risk of developing HCC, and subsequently induce ER stress, leading to the expression of GRP78 [9-11].

In the previous projects, we focused on the possible association between HBV infection or HCC risk/prognosis and GRP78 polymorphism involving a new mutation (-87 T>A, from the estimated translation start site of GRP78 gene), or an intronic mutation (rs430397 G>A, in the intron 5 of GRP78 gene). These studies indicated that GRP78 was associated with HCC progression, but not associated with HBV infection [12,13]. As a part of series of studies about relationship of polymorphism(s) and stress-associated diseases, we hypothesized that polymorphisms in promoter and 3’ untranslated region (UTR), which were known to be involved in regulation of gene expression, may be contributing factors or markers of a stress-associated disease, such as virus infection. To test this possibility, we further compared GRP78 polymorphisms at seven common loci in the promoter region (rs391957, rs17840762, rs17840761, rs11355458) and the 3’ UTR (rs16927997, rs1140763, rs12009) between chronic HBV carriers and healthy subjects, and to reveal the possible association between HBV infection and GRP78 gene.

**Methods**

**Subjects**

496 Han patients with chronic HBV infection as case series who had been treated as inpatients or outpatients were enrolled in several affiliated hospitals of Guangzhou Medical College between January 2001 and April 2005. The diagnosis of chronic HBV infection was based on the presence of HBsAg and HBeAg, or HBsAg and anti-HBe, together with the absence of anti-HBs, for at least 36 months (according to the corresponding inpatient and outpatient records) prior to enrolment. All these were tested to exclude hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection, the presence of autoimmune hepatitis, and/or alcohol consumption exceeding 8 g per day and other conspicuous diseases. Patients who received antiviral therapy including interferon or nucleoside analogues within one year of enrollment were also excluded.

539 unrelated healthy HBV non-infected controls were recruited from Han volunteer blood donors in above hospitals and the Department of Cancer, Zhongshan School of Medicine in Sun Yat-sen University in the same time. The controls were negative for HBsAg, anti-HBs and anti-HBc, with normal serum alanine aminotransferase (ALT) levels. These subjects were members of the health-care staff of the hospitals who were periodically monitored for professional exposure to hepatitis viruses. A standard informed consent, was given to the participants, after the nature of study had been fully explained. The study was performed with the approval of the ethical committee of Guangzhou Medical College and adhered to the tenets of the Declaration of Helsinki.

**Genotyping**

Genomic DNA was extracted from peripheral blood leukocytes using QIAGEN QIAamp DNA Mini Blood Kit (Hilden, Germany). The SNPs were detected by the TaqMan Assay-by-Design service (Applied Biosystems, Foster City, CA). The details of sequences and reaction conditions are available upon request https://products.appliedbiosystems.com/ab/en/US/adirect/ab. PCR was performed using the TaqMan Universal Master Mix without UNG on the ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA) and heated to 95°C for 10 minutes followed by 40 cycles of 92°C for 15 seconds and 60°C for 1 minute.

**Haplotype and diplotype construction**

Haplotype frequencies and pairwise linkage disequilibrium (LD) matrices were determined using the Haploview version 3.2.0 (Whitehead Institute for Biomedical Research, USA)[14]. Magnitudes of LD were represented by the standardized LD coefficients, complete association (D’) and absolute association (r²) [15-17]. The frequencies closely agreed with results from a maximum likelihood method implemented via an expectation-maximization (EM) algorithm[18]. Haplotypes and diplotypes were selected according to the corresponding occurring probabilities with a higher likelihood (> 0.95 as cut-point) [19].

**Table 1: Characterization of the participants**

| Characteristics | Cases (%) | Controls (%) | P     |
|-----------------|-----------|--------------|-------|
| n               | 496       | 539          |       |
| Age (mean ± SD) | 41.9 ± 13.5 | 43.0 ± 9.7  | 0.130³ |
| Gender          |           |              |       |
| Females         | 193 (38.91) | 232 (43.04) |       |
| Males           | 303 (61.09) | 307 (56.96) | 0.177³ |
| ALT (U/L, means ± SD) | 147.1 ± 95.5 | 26.7 ± 11.4 | 0.008³ |
| HBsAg (+)       | 496 (100%) | 0            |       |
| anti-HBs (+)    | 0         | 0            |       |
| HBeAg (+)       | 193 (38.91) | 0           |       |
| anti-HBe (+)    | 303 (61.09) | 0           |       |

Abbreviations: SD, standard deviation; ALT, alanine aminotransferase.  
³Mann-Whitney test; ³Pearson Chi-square test.
Statistical analysis
Chi-square test was used to determine whether there is a significant difference between cases and controls in terms of gender. Mann-Whitney U-test was used to test the difference among the age groups. Hardy-Weinberg equilibrium (HWE) of genotype distribution among cases or controls was carried out using Pearson Chi-square test. Logistic regression analysis was used to estimate odds ratios (ORs) and corresponding 95% confidence intervals (CIs) comparing cases to controls in association with genotypes, haplotypes and diplotypes using dominant, recessive and co-dominant models, respectively, adjusted for age and sex. All statistical tests were 2-sided and statistical significance was taken as \( P \text{-value} < 0.05 \).

Results
In the cases, the age at diagnosis ranged 25.5-59.8 years, the mean age was 41.9 (± 13.5) years, and the gender (male/female) ratio was 1.57:1. In the controls, the age ranged 27.0-56.2 years, the mean age was 43.0 (± 9.7) years, and the gender ratio was 1.32:1. The cases and the controls were frequency-matched by age (± 5 years, \( P = 0.130 \)) and gender (\( P = 0.177 \)), but not by serum ALT levels (\( P = 0.008 \)) (Table 1).

Genotyping data for each single-nucleotide polymorphism (SNP) were successfully obtained for 100% of the subjects. The distribution of the genotypes in controls and cases did not deviate from that expected by Hardy-Weinberg equilibrium (data not shown). Table 2 showed

Table 2: Genotype frequencies of GRP78 among cases and controls, and risk of HBV

| Loci        | Genotypes | Cases (%) | Controls (%) | OR (95% CI) | \( P \) |
|-------------|-----------|-----------|--------------|-------------|-------|
| rs391957    | GG        | 275 (54.95) | 320 (59.22) | 1           |       |
|             | AG        | 198 (40.00) | 200 (37.24) | 1.22 (0.94-1.59) | 0.137 |
|             | AA        | 23 (5.05)   | 19 (3.54)   | 1.60 (0.84-3.07) | 0.354 |
| p-trend\( ^\text{a} \) |           |            |             | 0.106       |       |
| rs17840762  | CC        | 334 (67.39) | 366 (67.97) | 1           |       |
|             | CT        | 144 (29.19) | 151 (27.93) | 1.05 (0.79-1.39) | 0.659 |
|             | TT        | 18 (3.42)   | 22 (4.10)   | 0.78 (0.41-1.51) | 0.271 |
| p-trend\( ^\text{a} \) |           |            |             | 0.501       |       |
| rs17840761  | TT        | 130 (25.76) | 156 (28.86) | 1           |       |
|             | CT        | 236 (47.74) | 249 (46.37) | 1.17 (0.87-1.59) | 0.405 |
|             | CC        | 130 (26.48) | 134 (24.77) | 1.24 (0.88-1.75) | 0.222 |
| p-trend\( ^\text{a} \) |           |            |             | 0.245       |       |
| rs11355458  | d         | 275 (54.95) | 320 (59.22) | 1           |       |
|             | G         | 198 (40.00) | 200 (37.24) | 1.22 (0.94-1.59) | 0.137 |
|             | GG        | 23 (5.05)   | 19 (3.54)   | 1.60 (0.84-3.07) | 0.354 |
| p-trend\( ^\text{a} \) |           |            |             | 0.254       |       |
| rs16927997  | TT        | 440 (88.83) | 480 (89.01) | 1           |       |
|             | CT        | 52 (10.45)  | 55 (10.24)  | 1.01 (0.67-1.53) | 0.812 |
|             | CC        | 4 (0.72)    | 4 (0.74)    | 1.04 (0.23-4.68) | 0.460 |
| p-trend\( ^\text{a} \) |           |            |             | 0.93        |       |
| rs1140763   | TT        | 129 (25.40) | 168 (31.10) | 1           |       |
|             | CT        | 236 (48.29) | 246 (45.62) | 1.36 (0.92-1.79) | 0.348 |
|             | CC        | 131 (26.31) | 125 (23.28) | 1.51 (0.95-2.06) | 0.177 |
| p-trend\( ^\text{a} \) |           |            |             | 0.394       |       |
| rs12009     | TT        | 166 (31.61) | 204 (37.80) | 1           |       |
|             | CT        | 222 (45.59) | 237 (43.95) | 1.25 (0.88-1.61) | 0.291 |
|             | CC        | 108 (21.80) | 98 (18.25)  | 1.53 (0.96-2.08) | 0.097 |
| p-trend\( ^\text{a} \) |           |            |             | 0.082       |       |

Note: OR, odds ratio; d, delete base.

\(^\text{a} \)Test for trend of odds was two sided and was based on likelihood ratio tests assuming a multiplicative model for all cases.
the distribution of genotypic frequencies of the 7 SNPs in chronic HBV patients and control subjects. No statistically significant differences were found between cases and controls in any of the dominant, codominant or recessive genotype models as well as the presence of single variant alleles ($p$-trend > 0.05, respectively).

LD reflects the non random association of alleles at two or more loci. Pair-wise LD analysis in 439 chronic HBV carriers showed the two blocks (block 1, promoter, including rs391957, rs17840762, rs17840761 and rs11355458; Block 2, 3’ UTR, including rs16927997, rs1140763 and rs12009) which are designed according to the internally developed solid spine of LD (Figure 1). Rs391957 and rs11355458 were completely linked ($r^2 = 1.00$) and rs1140763 and rs12009 were in high linkage disequilibrium ($r^2 = 0.785$) in these carriers.

Because genetic effects are not exerted individually, we considered the combined effects of all SNPs in this study according to the LD. There are 4 haplotypes and 9 diplotypes in the promoter region, and 3 haplotypes and 6 diplotypes in the 3’ UTR were constructed based on the 7 SNPs with minor allelic frequencies of above 1% in the chronic HBV carriers. The distributions of haplotypes and diplotypes exhibited no significant differences from the risk of HBV infection ($p$-trend > 0.05, respectively, Table 3 and Table 4).

**Discussion**

This was one of the series of studies to investigate the association between *GRP78* polymorphisms and risk of HBV infection. In this case-control study, there were no significant differences in risk of HBV associated with SNPs at any of these loci in the promoter and the 3’ UTR of *GRP78* gene. A single SNP usually provides a little information. If more SNPs are unified to construct haplotypes and diplotypes, they would supply more information and make up for short-coming of single SNP [20-22]. The SNPs identified in this study comprised 4 haplotypes

![Diagram](image)

**Figure 1** Linkage disequilibrium (LD) pattern ($r^2$ plots) of the SNPs in the promoter and 3’ UTR of *GRP78* gene among the 496 chronic HBV carriers, as generated by Haploview v3.2. Coding exons are marked by shaded blocks. The blocks are designed according to the internally developed solid spine of LD. The value within each diamond represents the pairwise correlation between pairs of SNPs (measured as 100 x $r^2$) defined by the upper left and the upper right sides of the diamond. The diamond without a number corresponds to $r^2 = 1$.

**Table 3: Haplotype frequencies in the promoter region and the 3’ UTR of *GRP78* gene in HBV carriers and controls, and risk of HBV**

| Haplotypes | Cases (%) | Controls (%) | OR (95% CI) | $P$ |
|------------|-----------|--------------|-------------|-----|
| **Promoter** |           |              |             |     |
| G-C-T-d    | 496 (49.64) | 561 (51.96)  | 1           |     |
| A-C-C-G    | 244 (25.04) | 238 (22.16)  | 1.26 (0.92-1.58) | 0.107 |
| G-T-C-d    | 180 (18.02) | 195 (18.08)  | 1.05 (0.80-1.35) | 0.376 |
| G-C-C-d    | 72 (7.30)   | 84 (7.82)    | 0.95 (0.71-1.32) | 0.552 |
| **p-trend** |           |              | 0.247       |     |
| **3’ UTR** |           |              |             |     |
| T-T-T      | 494 (49.55) | 582 (53.91)  | 1           |     |
| T-C-C      | 438 (44.50) | 433 (40.22)  | 1.15 (0.87-1.46) | 0.269 |
| C-C-T      | 60 (5.95)   | 63 (5.87)    | 1.21 (0.76-1.65) | 0.122 |
| **p-trend** |           |              | 0.181       |     |

Note: OR, odds ratio, d, delete base.

*Test for trend of odds was two sided and was based on likelihood ratio tests assuming a multiplicative model for all cases.*
and 9 diplotypes in the promoter region, and 3 haplotypes and 6 diplotypes in the 3’ UTR. By analyzing the associations between haplotypes/diplotypes and chronic HBV infection, however, no association were found.

The **GRP78** promoter contains three ER stress response elements (ERSEs) consisting of a tripartite structure CCAATN9CCACG, with N being 9-bp GC-rich region [23]. The four SNPs examined located not within but upstream of ERSE. **GRP78** promoter haplotypes may affect the individual variability of ER stress response and has been reported to be a potential risk factor for bipolar disorder in a Japanese population [24]. These suggested that the promoter haplotypes in the **GRP78** gene were significantly associated with the functional SNPs, which were involved in the promoter activity. However, our study did not demonstrate an association between the promoter haplotypes and diplotypes with chronic HBV infection in our Chinese population.

A number of contingent environmental conditions, among which infectious diseases may have been the most powerful, have exerted variable pressures on the human genome and favored the selection of alleles interfering with disease physiopathology. **GRP78** has recently emerged as an intracellular antiviral factor against HBV [6]. HBV invasion and other physiopathologic changes cause large amount of unfolding or false-folding protein accumulation in the ER, which in turn induces expression of **GRP78** [27]. **GRP78** pathway was one of the most important responders to virus-associated stress [28,29]. But the mechanism was controversial. Possibly, **GRP78** enhance primary immune protection against HBV. But its polymorphisms do not play more important roles during the chronic inflammation process. However, additional studies from larger populations among Han Chinese, and from diverse ethnic populations, are warranted before the

### Table 4: Diplotype frequencies in the promoter region and the 3’ UTR of **GRP78** gene in HBV carriers and controls, and risk of HBV

| Diplotypes      | Cases (%) | Controls (%) | OR (95% CI) | p   |
|-----------------|-----------|--------------|-------------|-----|
| **Promoter**    |           |              |             |     |
| GCTd/GCTd       | 130 (25.77)| 156 (28.86)  | 1           |     |
| ACCG/GCTd       | 123 (24.86)| 128 (23.84)  | 1.20 (0.83-1.76) | 0.196 |
| GCTd/GTCd       | 75 (15.14) | 81 (14.90)   | 1.11 (0.74-1.65) | 0.153 |
| ACCG/GTCd       | 55 (11.17) | 49 (9.12)    | 1.57 (0.97-2.55) | 0.462 |
| GCCd/GCTd       | 38 (7.75)  | 40 (7.45)    | 1.19 (0.72-2.07) | 0.259 |
| ACCG/GCCd       | 20 (3.96)  | 23 (4.28)    | 1.04 (0.53-2.00) | 0.754 |
| GTCd/GTCd       | 18 (3.42)  | 22 (4.10)    | 0.89 (0.45-1.75) | 0.410 |
| GCCd/GTCd       | 14 (2.88)  | 21 (3.91)    | 0.84 (0.41-1.72) | 0.388 |
| ACCG/ACCG       | 23 (5.05)  | 19 (3.54)    | 1.66 (0.85-3.24) | 0.071 |
| **p-trend**     |           |              | 0.142       |     |
| **3’ UTR**      |           |              |             |     |
| TCC/TTT         | 203 (41.62)| 214 (39.66)  | 1           |     |
| TTT/TTT         | 129 (25.41)| 168 (31.10)  | 1.30 (0.95-1.80) | 0.249 |
| TCC/TCC         | 108 (21.80)| 98 (18.25)   | 1.50 (0.75-2.28) | 0.166 |
| CCT/TTT         | 33 (6.67)  | 32 (5.96)    | 1.43 (0.82-2.46) | 0.215 |
| CCT/TCC         | 19 (3.78)  | 23 (4.28)    | 0.97 (0.55-2.13) | 0.647 |
| CCT/CCT         | 4 (0.72)   | 4 (0.74)     | 1.36 (0.26-6.08) | 0.076 |
| **p-trend**     |           |              | 0.091       |     |

Note: OR, odds ratio; d, delete base.

*Test for trend of odds was two sided and was based on likelihood ratio tests assuming a multiplicative model for all cases.*
importance of GRP78 polymorphisms in chronic HBV risk can be fully ascertained.

Conclusion
In conclusion, the present study suggests that the GRP78 polymorphisms are not associated with chronic HBV infection. These data, however, do not exclude a possible physiopathological role of these SNPs in the progression of chronic HBV infection.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
ZX and LDP participated of the study design and performed the genotyping. FWG and HJQ performed the statistical analysis. WJL and LSQ participated in the coordination and sample collection. LMCM and KHF drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements
We are grateful to all the patients and the physicians who were involved in sample collection for the study. This work was supported by direct grant from Guangzhou Medical College.

Author Details
1Institute of Oncology, Affiliated Tumor Hospital, Guangzhou Medical College, Guangzhou, PR China. 2Zhejiang University, School of Medicine, Sun Yat-sen University, Guangzhou, PR China. 3The Brain Tumor Center and Neurosurgery Division, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, PR China. 4Stanley Ho Center for Emerging Infectious Diseases, and Li Ka Shing Institute of Medical Sciences, The Chinese University of Hong Kong, Hong Kong, PR China and 5Open Laboratory of Chemical Biology, Institute of Molecular Technology, Department of Chemistry, The University of Hong Kong, Pokfulam, Hong Kong, PR China

Received: 19 December 2009 Accepted: 2 June 2010 Published: 2 June 2010

References
1. Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009, 49:513-21.
2. Balsano C, Alisi A. Viral hepatitis B: established and emerging therapies. Curr Med Chem 2008, 15:930-939.
3. Lolekha S, Warachit B, Hirunyachote A, Bowonkiratikachorn P, West DJ, Infante J, Berciano J, Combarros O. No association of CDK5 genetic variants with Alzheimer's disease risk. BMC Med Genet 2009, 10:68.
4. Wang HC, Huang W, Lai MD, Su U. Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis. Cancer Sci 2010, 99:7683-688.
5. Liang TJ, Beral J, Combarros O. Identification of the cis-acting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose-regulated proteins. J Biol Chem 1998, 273:3739-3743.
6. Green J, Khabar KS, Koo BC, Williams BR, Poljak SJ. Stability of CCL-8 and related human and mouse mRNAs in the context of hepatic C virus replication in vitro. J Infect Dis 2006, 193:802-811.
7. Wang HC, Huang W, Lai MD, Su U. Hepatitis B virus pre-S mutants in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis 2004, 25:2023-2032.
8. Wang HC, Huang W, Lai MD, Su U. Hepatitis B virus pre-S mutants in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis 2004, 25:2023-2032.
9. Liang TJ, Beral J, Combarros O. Identification of the cis-acting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose-regulated proteins. J Biol Chem 1998, 273:3739-3743.
10. Wang HC, Huang W, Lai MD, Su U. Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis. Cancer Sci 2010, 99:7683-688.